Travere Therapeutics upgraded by Guggenheim with a new price target
$TVTX
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim upgraded Travere Therapeutics from Neutral to Buy and set a new price target of $25.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2025 | $30.00 | Buy | H.C. Wainwright |
| 6/11/2025 | $35.00 → $32.00 | Buy | Citigroup |
| 1/10/2025 | Overweight | Cantor Fitzgerald | |
| 10/21/2024 | $9.00 → $27.00 | Equal Weight → Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/9/2024 | $25.00 | Neutral → Buy | Guggenheim |
| 3/27/2024 | Buy → Neutral | Guggenheim | |
| 12/5/2023 | $7.00 → $10.00 | Neutral → Buy | Citigroup |
S-8 - Travere Therapeutics, Inc. (0001438533) (Filer)
8-K - Travere Therapeutics, Inc. (0001438533) (Filer)
8-K - Travere Therapeutics, Inc. (0001438533) (Filer)
H.C. Wainwright resumed coverage of Travere Therapeutics with a rating of Buy and set a new price target of $30.00
Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $32.00 from $35.00 previously
Cantor Fitzgerald initiated coverage of Travere Therapeutics with a rating of Overweight
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 81,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant dat
New data from Phase 2 SPARTAN Study show antifibrotic and anti-inflammatory action of FILSPARI and its impact on B cell and complement pathways in IgAN Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the Company will present three abstracts on the effect of FILSPARI (sparsentan) in rare kidney disease at the upcoming International Podocyte Conference in Hamburg, Germany, June 10-13, 2025. The Company will present new data evaluating biomarkers of disease progression in IgA nephropathy (IgAN) from the Phase 2 SPARTAN Study showing rapid and sustained reductions in urinary BAFF and sC5b9 as well as reductions in proinflammatory and profibrotic biomarkers after starting FILS
Grammy-winning producer and platinum recording artist joins forces with patient advocate and singer-songwriter to transform the invisible struggle of FSGS into a creative movement New campaign aims to unite the FSGS community and inspire patients and caregivers to share their journeys Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the launch of a new awareness campaign, "Play It Forward," to bring hope and encouragement to the focal segmental glomerulosclerosis (FSGS) community. FSGS is a rare kidney disease (RKD) affecting children and adults and a leading cause of kidney failure. This press release features multimedia. View the full release here: https://www.businesswire.co
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)